To Assess the Efficacy of Early Administration of Energy Enriched and Protein Enriched Formula in Post Cardiac Repair Infants: a Randomized Controlled Trial, Comparative Study

Sponsor
King Faisal Specialist Hospital & Research Centre, Jeddah (Other)
Overall Status
Recruiting
CT.gov ID
NCT05826769
Collaborator
(none)
60
1
2
31.7
1.9

Study Details

Study Description

Brief Summary

Congenital heart disease (CHD) is a public health problem, A substantial percentage of infants and toddlers with CHD undergo cardiopulmonary bypass surgery. Undernutrition affects up to 90% of these patients, and it's contributed to worse surgical and neurological outcomes. Infants with CHD are typically delivered at full term with a normal birth weight. However, as time passes, their development may become stunted. There are no negotiated guidelines for nutritional monitoring and intervention in this age bracket of infants. Through the use of Energy Enriched and Protein Enriched nutrition formula during the postoperative phase, this has shown to be well tolerated and support in delivering higher nutrition intakes within the first days after surgery. The objective of this research is to assess the long term outcome of patients who have had energy- and protein-rich nutrition formulas post cardiac surgery. An open, 2-arm, randomized controlled trials will be conducted to assess the efficacy of early administration of energy enriched and protein enriched formula in post cardiac repair infants. The expected primary outcome is that intervention group will have good tolerance to feeding and the secondary outcome is the significant weight gain rate (weight velocity) in comparing to control groups

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Energy- Protein Enriched Nutritional Formula
N/A

Detailed Description

Due to a high incidence of 9/1000 live births, congenital heart disease (CHD) is a public health problem, A substantial percentage of infants and toddlers with CHD undergo cardiopulmonary bypass surgery. Undernutrition affects up to 90% of these patients, and it's contributed to worse surgical and neurological outcomes. Infants with CHD are typically delivered at full term with a normal birth weight. However, as time passes, their development may become stunted. There are no negotiated guidelines for nutritional monitoring and intervention in this age bracket of infants. Through the use of Energy Enriched and Protein Enriched nutrition formula during the postoperative phase, this has shown to be well tolerated and support in delivering higher nutrition intakes within the first days after surgery. Numerous clinical trials have been conducted (Zhang H et al., 2018; Scheeffer. et al., 2019) and were designed to explore the effects of early introduction of Energy Enriched and Protein Enriched formula (EP) to infants with CHD. The research found that feeding EP is correlated with improved weight gain and nutritional status, and also a decrease in Hospital Length Of Stay (HLOS) as well as antibiotic use, but this also causes increased feeding discomfort. The signs of feeding discomfort, on the other hand, were improved by medication and had little effect on feeding progress.

The objective of this research is to assess the long term outcome of patients who have had energy- and protein-rich nutrition formulas post cardiac surgery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients are randomized before surgery in blocks of 2 using a computer-generated randomization list into intervention and control groups This will be An open, 2-arm,randomized controlled trialPatients are randomized before surgery in blocks of 2 using a computer-generated randomization list into intervention and control groups This will be An open, 2-arm,randomized controlled trial
Masking:
None (Open Label)
Masking Description:
According to national regulations, distribution of infant formula inside the hospital without a proper label is not allowed; therefore, subjects can not be blinded in this study.
Primary Purpose:
Supportive Care
Official Title:
To Assess the Efficacy of Early Administration of Energy Enriched and Protein Enriched Formula in Post Cardiac Repair Infants: a Randomized Controlled Trial, Comparative Study
Actual Study Start Date :
Jul 21, 2021
Actual Primary Completion Date :
Jul 27, 2022
Anticipated Study Completion Date :
Mar 12, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Energy- Protein Enriched Nutritional Formula

Liquid, ready-to-use Energy-Protein nutrition formula with energy density of 1 kCal/mL (EP formula)

Dietary Supplement: Energy- Protein Enriched Nutritional Formula
EN volume will start at 1 mL/kg/h and then increase by 1 mL/kg every 6 hours if tolerated, until reaching 130 mL/kg/d.
Other Names:
  • High Calorie High Protein Nutritional Formula
  • No Intervention: Standard Nutritional Formula

    Polymeric formula stage-1 and stage-2 for infants aged 0-6 months and 6-12 months accordingly, providing 0.67 kCal/mL (S-1/S-2 formula)

    Outcome Measures

    Primary Outcome Measures

    1. after admission in ICU, will measure the Tolerability [5 days]

      Gastric tolerance

    Secondary Outcome Measures

    1. Weight gain rate [90 days]

      Weight velocity

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    4 Weeks to 1 Year
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. infants born at term, age between 4 weeks and 12 months

    2. post congenital heart surgery (RACHS score 2)

    Exclusion Criteria:
    1. syndromic patients

    2. if patient is on parenteral nutrition (PN)

    3. premature

    4. combined inherited metabolic or chromosomal diseases

    5. liver and kidney dysfunction before enrollment (index >2 times the upper limit of normal)

    6. upper GI activity, vomiting, diarrhea, bloating, and other symptoms before enrollment

    7. breastfeeding patients.

    8. cow's milk allergy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 KFSHRC Jeddah Outside North America Saudi Arabia

    Sponsors and Collaborators

    • King Faisal Specialist Hospital & Research Centre, Jeddah

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    King Faisal Specialist Hospital & Research Centre, Jeddah
    ClinicalTrials.gov Identifier:
    NCT05826769
    Other Study ID Numbers:
    • 2021-34
    First Posted:
    Apr 24, 2023
    Last Update Posted:
    Apr 24, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by King Faisal Specialist Hospital & Research Centre, Jeddah
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 24, 2023